Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections.

BioVaria will take place in a hybrid format on May 11 and 12, 2022 - live at the Sofitel in Munich and virtually. 14 technology transfer partners from five European countries will present more than 50 commercially attractive licensing opportunities. Application for the Startup Pitch & Partner programme is now open until March 1, 2022.

Céline Christiansen has joined the Berlin team as technology scout. She will closely work with MDC and Charité scientists, supporting them in all IP- and transfer-related aspects of their work.

The financing round was supported by a selected network of investors from medical and financial sectors. It enables the start-up to advance its fully automated ‘lab-in-a-box’ system for the molecular diagnosis of skin diseases to the market.

Supported by Ascenion, Matthias Bruhn and his team at TWINCORE - Centre for Experimental and Clinicial Infection Research have attracted EUR 97,000 to explore the commercial feasibility of their MEMUMAB project. The goal is to provide therapeutic antibodies against infectious diseases such as COVID-19.

On 30 November 2021, Ascenion will host the first GO-Bio Information Webinar as part of our BMBF-funded Life Science Digital Hub project. Participants…

Three projects from Ascenion’s partner institute have been awarded translational funding. Two of the teams hope to develop novel antivirals, the third is working to create a new diagnostic platform.

The company will use the proceeds to advance its groundbreaking optoacoustic imaging technology into clinical practice. If successful, it would provide a superior, non-invasive alternative to established diagnostic procedures in many diseases.

We have all seen the digital health trend approaching – but it has nevertheless surprised us with its speed and force. Here our summary of last year’s highlights, start-up projects and key figures, in the field of digital health and beyond.

The German Federal Ministry of Education and Research (BMBF) is providing EUR 6.5 million in funding for 10 selected research projects targeting long-term symptoms of COVID-19. Ascenion’s partner institutes are making significant contributions to three of these projects.

Ascenion welcomes two new colleagues: Rebecca Engels is coordinating Ascenion’s activities in the GO-Bio initial programme from our Munich office, and Arturo Robertazzi supports our Berlin team as technology manager.

Be part of Munich’s vibrant bioentrepreneurial ecosystem and sign up now! In 2021, the event will be delivered in a fully virtual format.

25 August 2021, Munich – Cardior Pharmaceuticals has closed a Series B financing round totalling EUR 64 million (USD 76 million). The round was led by…

The method, SARSeq (Saliva Analysis by RNA sequencing), enables highly sensitive, massively-parallel and cost-effective testing for SARS-CoV-2. Ascenion has supported its patent protection and licencing for commercial use in China.

The start-up has also been certified as a medical device manufacturer in the EU. Its x-c-bleeding product uses AI-based software to predict the risk of post-operative bleeding in patients in intensive care units.

Prague, Czech Republic

Ankara, Turkey

Cologne, Germany